disopyramide has been researched along with Heart Failure in 28 studies
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of intravenously administered disopyramide phosphate were evaluated in seven patients with refractory ventricular tachycardia." | 9.04 | Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia. ( Mason, DT; Miller, RR; Vera, Z; Vismara, LA, 1977) |
| "These previously unrecognized immunomodulatory effects of amiodarone may contribute to its beneficial effects in heart failure patients." | 7.69 | Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. ( Matsumori, A; Nishio, R; Nose, Y; Ono, K; Sasayama, S, 1997) |
| "A patient with ischemic cardiomyopathy and congestive heart failure was treated with disopyramide phosphate for ventricular arrhythmias." | 7.66 | Disopyramide-induced ventricular tachycardia. ( Gantz, KB; Lo, KS; Lucchesi, BR; Pitt, B; Stetson, PL, 1980) |
| "The parmacokinetics of disopyramide (DP) in 10 patients with imminent to moderate cardiac failure has been studied and compared with the results in normal volunteers." | 7.66 | Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure. ( Amlie, JP; Bredesen, JE; Landmark, K; Simonsen, S; Thaulow, E, 1981) |
| "The haemodynamic effects of disopyramide have been studied in 11 patients with manifest or imminent heart failure." | 7.65 | Haemodynamic effects of intravenous disopyramide in heart failure. ( Jensen, G; Sigurd, B; Uhrenholt, A, 1975) |
| "The management of syncope is clinically important for heart failure (HF) patients." | 5.72 | [Evaluation of Disopyramide Efficacy for Refractory Syncope in Heart Failure with Preserved Ejection Fraction Using Holter Electrocardiography: A Case Report]. ( Asai, Y; Sato, Y; Shintani, T; Yamamoto, T, 2022) |
| " The suggested dosage regimen of disopyramide seems to result in a satisfactory response." | 5.27 | Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure. ( Angelo, HR; Bonde, J; Bødtker, S; Kampmann, JP; Svendsen, TL, 1985) |
| "The effects of intravenously administered disopyramide phosphate were evaluated in seven patients with refractory ventricular tachycardia." | 5.04 | Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia. ( Mason, DT; Miller, RR; Vera, Z; Vismara, LA, 1977) |
| "These previously unrecognized immunomodulatory effects of amiodarone may contribute to its beneficial effects in heart failure patients." | 3.69 | Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. ( Matsumori, A; Nishio, R; Nose, Y; Ono, K; Sasayama, S, 1997) |
| "To study influence of congestive heart failure (CHF) and acute myocardial infarction (AMI) on alpha 1-acid glycoprotein (AGP) and sialic acid (SA) concentration, and binding of AGP to disopyramide (Dis)." | 3.69 | Serum alpha 1-acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients. ( Chu, JS; Kishion, S; Miyazaki, K; Nomura, A, 1997) |
| "The pharmacokinetics and bioavailability of total (bound plus unbound) and unbound disopyramide were compared following the simultaneous administration of an oral dose of disopyramide and an intravenous dose of 14C-disopyramide in five normal volunteers and in 11 patients with congestive heart failure." | 3.67 | Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. ( Haughey, DB; Leier, CV; Lima, JJ, 1984) |
| "A patient with ischemic cardiomyopathy and congestive heart failure was treated with disopyramide phosphate for ventricular arrhythmias." | 3.66 | Disopyramide-induced ventricular tachycardia. ( Gantz, KB; Lo, KS; Lucchesi, BR; Pitt, B; Stetson, PL, 1980) |
| "The parmacokinetics of disopyramide (DP) in 10 patients with imminent to moderate cardiac failure has been studied and compared with the results in normal volunteers." | 3.66 | Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure. ( Amlie, JP; Bredesen, JE; Landmark, K; Simonsen, S; Thaulow, E, 1981) |
| "The haemodynamic effects of disopyramide have been studied in 11 patients with manifest or imminent heart failure." | 3.65 | Haemodynamic effects of intravenous disopyramide in heart failure. ( Jensen, G; Sigurd, B; Uhrenholt, A, 1975) |
| " On the other hand, the elimination half-life of antiarrhythmic agents that have a large volume of distribution and are highly cleared by the liver may be twice as long in patients with CHF compared with normal subjects." | 2.37 | Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. ( Echt, DS; Roden, DM; Woosley, RL, 1986) |
| "The management of syncope is clinically important for heart failure (HF) patients." | 1.72 | [Evaluation of Disopyramide Efficacy for Refractory Syncope in Heart Failure with Preserved Ejection Fraction Using Holter Electrocardiography: A Case Report]. ( Asai, Y; Sato, Y; Shintani, T; Yamamoto, T, 2022) |
| "Milrinone (M) has been shown to improve left ventricular (LV) performance in animal and human studies." | 1.27 | Evaluation of the vasodilator vs inotropic effect of milrinone using an animal model of left ventricular failure: reversal of disopyramide depression of the myocardium with milrinone. ( Berdoff, R; Goldberg, E; Haimowitz, A; Spivack, G; Tay, S, 1987) |
| " The suggested dosage regimen of disopyramide seems to result in a satisfactory response." | 1.27 | Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure. ( Angelo, HR; Bonde, J; Bødtker, S; Kampmann, JP; Svendsen, TL, 1985) |
| "Underventilation and cardiac arrhythmias were observed only in the agonal phase after several minutes of circulatory arrest." | 1.26 | Cardiac consequences and treatment of disopyramide intoxication: experimental evaluation in dogs. ( Hayler, AM; Holt, DW; Medd, RK; O'Keeffe, B, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (75.00) | 18.7374 |
| 1990's | 4 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (3.57) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Asai, Y | 1 |
| Shintani, T | 1 |
| Yamamoto, T | 1 |
| Sato, Y | 1 |
| Owens, AT | 1 |
| Masri, A | 1 |
| Abraham, TP | 1 |
| Choudhury, L | 1 |
| Rader, F | 1 |
| Symanski, JD | 1 |
| Turer, AT | 1 |
| Wong, TC | 1 |
| Tower-Rader, A | 1 |
| Coats, CJ | 1 |
| Fifer, MA | 1 |
| Olivotto, I | 1 |
| Solomon, SD | 1 |
| Watkins, HC | 1 |
| Heitner, SB | 1 |
| Jacoby, DL | 1 |
| Kupfer, S | 1 |
| Malik, FI | 1 |
| Meng, L | 1 |
| Sohn, R | 1 |
| Wohltman, A | 1 |
| Maron, MS | 1 |
| Hamada, M | 1 |
| Ikeda, S | 1 |
| Shigematsu, Y | 1 |
| Theisen, K | 1 |
| Lo, KS | 1 |
| Gantz, KB | 1 |
| Stetson, PL | 1 |
| Lucchesi, BR | 1 |
| Pitt, B | 1 |
| Lima, JJ | 1 |
| Haughey, DB | 1 |
| Leier, CV | 1 |
| Swiryn, S | 1 |
| Bauernfeind, RA | 1 |
| Strasberg, B | 1 |
| Palileo, E | 1 |
| Iverson, N | 1 |
| Levy, PS | 1 |
| Rosen, KM | 1 |
| Landmark, K | 1 |
| Bredesen, JE | 1 |
| Thaulow, E | 1 |
| Simonsen, S | 1 |
| Amlie, JP | 1 |
| Desai, JM | 1 |
| Scheinman, MM | 1 |
| Hirschfeld, D | 1 |
| Gonzalez, R | 1 |
| Peters, RW | 1 |
| Kannelønning, KS | 1 |
| Podrid, PJ | 1 |
| Schoeneberger, A | 1 |
| Lown, B | 1 |
| Matsumori, A | 1 |
| Ono, K | 1 |
| Nishio, R | 1 |
| Nose, Y | 1 |
| Sasayama, S | 1 |
| Chu, JS | 1 |
| Kishion, S | 1 |
| Nomura, A | 2 |
| Miyazaki, K | 2 |
| Dreifus, LS | 1 |
| Nies, AS | 1 |
| Gal, J | 1 |
| Gerber, JG | 1 |
| Vismara, LA | 1 |
| Vera, Z | 1 |
| Miller, RR | 1 |
| Mason, DT | 1 |
| Story, JR | 1 |
| Abdulla, AM | 1 |
| Frank, MJ | 1 |
| O'Keeffe, B | 1 |
| Hayler, AM | 1 |
| Holt, DW | 1 |
| Medd, RK | 1 |
| Goldman, P | 1 |
| Ingelfinger, JA | 1 |
| Jutzy, RV | 1 |
| Pugh, DM | 1 |
| Jensen, G | 2 |
| Uhrenholt, A | 2 |
| Sigurd, B | 1 |
| Yasuda, H | 1 |
| Kobayashi, T | 1 |
| Kishino, S | 1 |
| Kohri, N | 1 |
| Iseki, K | 1 |
| Oźarek-Medyńska, T | 1 |
| Krynicki, M | 1 |
| Polubiec, A | 1 |
| Woosley, RL | 1 |
| Echt, DS | 1 |
| Roden, DM | 1 |
| Goldberg, E | 1 |
| Berdoff, R | 1 |
| Spivack, G | 1 |
| Haimowitz, A | 1 |
| Tay, S | 1 |
| Bonde, J | 1 |
| Angelo, HR | 1 |
| Bødtker, S | 1 |
| Svendsen, TL | 1 |
| Kampmann, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial[NCT02948998] | Phase 4 | 260 participants (Anticipated) | Interventional | 2018-05-14 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for disopyramide and Heart Failure
| Article | Year |
|---|---|
Advances in medical treatment of hypertrophic cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Calcium Channel Blocke | 2014 |
Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Digitalis; Disopyramide; Drug Interactions; Encainide; | 1986 |
3 trials available for disopyramide and Heart Failure
| Article | Year |
|---|---|
Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia.
Topics: Aged; Clinical Trials as Topic; Coronary Disease; Disopyramide; Drug Evaluation; Heart Failure; Huma | 1977 |
Clinical studies of Norpace (Part IV).
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Clinical Trials as T | 1975 |
Clinical studies of Norpace (Part VI).
Topics: Adult; Anti-Arrhythmia Agents; Anticoagulants; Arrhythmias, Cardiac; Bradycardia; Clinical Trials as | 1975 |
23 other studies available for disopyramide and Heart Failure
| Article | Year |
|---|---|
[Evaluation of Disopyramide Efficacy for Refractory Syncope in Heart Failure with Preserved Ejection Fraction Using Holter Electrocardiography: A Case Report].
Topics: Aged, 80 and over; Disopyramide; Electrocardiography, Ambulatory; Heart Failure; Humans; Male; Strok | 2022 |
Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3.
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Disopyramide; Heart Failure; Humans; Sequoia | 2023 |
[Pharmacotherapy of paroxysmal tachycardia].
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Atrial Flutter; Digitalis Glycosides; Disopyramide | 1983 |
Disopyramide-induced ventricular tachycardia.
Topics: Alcoholism; Cardiac Complexes, Premature; Cardiomyopathies; Coronary Disease; Disopyramide; Heart Fa | 1980 |
Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.
Topics: Adult; Aged; Biological Availability; Blood Proteins; Body Weight; Carbon Radioisotopes; Disopyramid | 1984 |
Prediction of response to class I antiarrhythmic drugs during electrophysiologic study of ventricular tachycardia.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Disopyramide; Dose-Response Relationship, Drug; Ele | 1982 |
Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Biological Availability; Disopyramide; Fema | 1981 |
Cardiovascular collapse associated with disopyramide therapy.
Topics: Administration, Oral; Aged; Arrhythmias, Cardiac; Disopyramide; Electrocardiography; Female; Heart A | 1981 |
[Cardiac shock after disopyramide].
Topics: Disopyramide; Heart Block; Heart Failure; Humans; Male; Middle Aged; Pyridines; Shock, Cardiogenic | 1981 |
Congestive heart failure caused by oral disopyramide.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Disopyramide; Female; Heart Failure; Humans | 1980 |
Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure.
Topics: Amiodarone; Anti-Arrhythmia Agents; Disopyramide; Dose-Response Relationship, Drug; Heart Failure; H | 1997 |
Serum alpha 1-acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients.
Topics: Adult; Aged; Disopyramide; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; | 1997 |
Clinical studies of Norpace (Part X).
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Complexes | 1975 |
Complications of disopyramide therapy.
Topics: Bundle-Branch Block; Confusion; Disopyramide; Heart Failure; Humans; Male; Middle Aged; Propranolol; | 1979 |
Cardiogenic shock and disopyramide phosphate.
Topics: Acute Disease; Arrhythmias, Cardiac; Cardiac Output; Disopyramide; Heart Failure; Humans; Kidney Fai | 1979 |
Cardiac consequences and treatment of disopyramide intoxication: experimental evaluation in dogs.
Topics: Animals; Arrhythmias, Cardiac; Disopyramide; Dogs; Dopamine; Electrocardiography; Glucagon; Heart Ar | 1979 |
Therapy with antiarrhythmic drugs.
Topics: Acetylation; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Heart Failure; Humans; Indo | 1978 |
Circulatory effects of intravenous disopyramide in heart failure.
Topics: Blood Pressure; Cardiac Output; Disopyramide; Heart Failure; Heart Rate; Hemodynamics; Humans; Injec | 1976 |
Haemodynamic effects of intravenous disopyramide in heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Disopyramide; Electrocardiography; Female; Heart Failur | 1975 |
Serum alpha-1-acid glycoprotein and protein binding of disopyramide in patients with congestive heart failure.
Topics: Aged; Disopyramide; Heart Failure; Humans; Middle Aged; Orosomucoid; Protein Binding | 1992 |
Results of the treatment of cardiac arrhythmias with Palpitin.
Topics: Adult; Aged; Arrhythmias, Cardiac; Coronary Disease; Disopyramide; Female; Heart Failure; Humans; Hy | 1990 |
Evaluation of the vasodilator vs inotropic effect of milrinone using an animal model of left ventricular failure: reversal of disopyramide depression of the myocardium with milrinone.
Topics: Animals; Cardiac Output; Cardiotonic Agents; Depression, Chemical; Disease Models, Animal; Disopyram | 1987 |
Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure.
Topics: Aged; Disopyramide; Heart Failure; Humans; Kinetics; Metabolic Clearance Rate; Middle Aged; Myocardi | 1985 |